| Press
Releases
April 14, 2010
NeuroHealing Pharmaceuticals Announces Publication Supporting the Use of NH001 to Treat Patients in a Coma and Issuance of NH001 Patent
August 21, 2009
NeuroHealing Announces Formation of Medical Advisory Board for NH02D Program
June 9, 2009
Interim Results of Phase II Trial for the Treatment of Sialorrhea to be Presented at Movement Disorder Society International Congress June 11th
April 13, 2009
NeuroHealing to Present Data on NH02D Premature Ejaculation Drug at AUA Meeting
February 2, 2009
NeuroHealing Appoints David Gwynne, VP Business Development, to Initially Focus on NH02D Program for Premature Ejaculation
September 24, 2008
NeuroHealing Pharmaceuticals to Present at Drug Repositioning Summit in Boston, October 6-7, 2008
August 11, 2008
Industry Leaders Select NeuroHealing’s NH001 Among Top 10 Most Promising Neuroscience Projects Available for Partnering
July 22, 2008
Life Science Angels Makes Additional Investment in NeuroHealing Pharmaceuticals
July 16, 2008
NeuroHealing Pharmaceuticals Receives Grant from the FDA Office of Orphan Drugs for Clinical Development of NH001 to Treat Patients in a Vegetative and Minimally Conscious State
February 19, 2008
NeuroHealing Pharmaceuticals Initiates Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease Patients
January 3, 2008
NeuroHealing Pharmaceuticals Appoints Burt Adelman, M.D. to Board of Directors
December 13, 2007
The Michael J. Fox Foundation Awards Funding To NeuroHealing Pharmaceuticals Researchers for a Phase II Clinical Trial of NH004 for Sialorrhea Control in Parkinson's Disease Patients
March 12, 2007
NeuroHealing Pharmaceuticals Presents Clinical Data for NH001 in Coma Recovery
at the American Society for Experimental NeuroTherapeutics (ASENT) Annual Meeting
September 12, 2006
NeuroHealing Pharmaceuticals CEO, Neal Farber, to Speak at the Dow Jones VentureWire Health Care Innovations 2006 Conference, the Biotech & Life Sciences Global Venture Congress 2006, and the Life Sciences Venture Summit 2006
May 25, 2006
NeuroHealing Receives Orphan Drug Designation for NH001 for Patients in Vegetative State or Minimally Conscious State
April 5, 2006
Life Science Angels Invests in NeuroHealing Pharmaceuticals
February 10, 2006
NeuroHealing to Present at 4th World NeuroRehabilitation Congress, Hong Kong, Feb 12-16 2006
January 17, 2006
NeuroHealing Announces IND Clearance for NH001 for Coma Patients
November 3, 2005
NeuroHealing to Present at Rodman & Renshaw Techvest Conference
August 31, 2005
NeuroHealing Announces IND Submission for NH001 for Coma Patients
December 8, 2004
NeuroHealing Commences Clinical Trial of NH001 for Coma Patients
June 14, 2004
Harvard Biotechnology Club Awards NeuroHealing Pharmaceuticals
First Prize in Business Plan Competition
In the News
March 12, 2010, Scientific American
Consciousness-Raising: Kick-Starting the Brain's Dopamine System May Revive Some Vegetative Patients
May 31, 2008, Neurotech Insights
NeuroHealing: Awakening Consciousness
September 8, 2006, New York Times
Mental Activity Seen in a Brain Gravely Injured September 9, 2005, BioWorld Today
NeuroHealing tackling brain injury with dopamine agonist
May 1, 2005, Start-Up Magazine
Jumpstarting the brain's healing - NeuroHealing profiled in Start-Up Magazine
March 8, 2005, Business Wire
NeuroHealing selected to present at "Best in Show Competition" in EC21 BioVentures Conference in London - March 22, 2005
December 20, 2004, Mass High Tech
Company Targets Coma Patients with Compound
October 4, 2004, Forbes Magazine
Twilight
Zone
June 7, 2004, IN VIVO
Selected Start-Ups
June 28, 2004, Mass High Tech
NeuroHealing
Pharmaceuticals Focuses on Coma Recovery Treatment
May 2004 - GSAS Harvard Biotechnology Club
Neurohealing
Pharmaceuticals - FIRST PLACE
|
